Salix Highlights Xifaxan Study Results

February 2011
Chain Drug Review;2/28/2011, Vol. 33 Issue 4, p48
Trade Publication
The article reports that Salix Pharmaceuticals Ltd. has noted that the New England Journal of Medicine has published results of the company's efficacy and safety studies of Xifaxan 550 mg tables in treating irritable bowel syndrome (IBS) without constipation in the U.S.


Related Articles

  • Evaluation and management of irritable bowel syndrome.  // American Family Physician;5/15/1994, Vol. 49 Issue 7, p1650 

    Refers to a study published in the December 23, 1993 issue of the periodical `New England Journal of Medicine' regarding the evaluation and management of irritable bowel syndrome. Lack of specific structural or biochemical causes; Abdominal pain associated with a change in bowel as the most...

  • Salix's Rifaximin IBS Data Bring Strong Share Bump.  // BioWorld Today;10/7/2008, Vol. 19 Issue 195, p2 

    The article reports that shares of Salix Pharmaceuticals Ltd. rose $1.38, or 24.3 percent, to close at $7.06, on news that a Phase II trial showed that diarrhea-predominant irritable bowel syndrome patients treated with Salix's rifaximin had statistically greater clinical improvement in quality...

  • Salix's Phase III Bowel Drug Shows Sustained Relief of IBS. Hollingsworth, Catherine // BioWorld Today;5/5/2010, Vol. 21 Issue 86, p1 

    The article reports on the results of the Phase III studies of Xifaxan/rifaximin from Salix Pharmaceuticals showing that the drug provided acute and sustained relief from nonconstipation irritable bowel syndrome (non-C IBS) symptoms. The conduct of the 14-day course of Xifaxan 550 milligrams...

  • Salix Liver-Failure Win Puts Spotlight on Xifaxan in IBS. Osborne, Randy // BioWorld Today;4/5/2010, Vol. 21 Issue 64, p1 

    The article reports on the approval of Salix Pharmaceuticals' antibiotic Xifaxan for irritable bowel syndrome (IBS). The studies TARGET 1 and TARGET 2 have met primary and secondary endpoints in IBS. There are three forms of IBS, namely, diarrhea-predominant, constipation-predominant and mixed,...

  • Salix Soars on Good Data from Phase III Studies.  // Bioworld Week;9/21/2009, Vol. 17 Issue 38, p2 

    The article reports on the positive results of the Phase III studies regarding the use of rifaximin conducted by Salix Pharmaceuticals Ltd. in Raleigh, North Carolina. It states that the trial administered to 600 patients indicate the significant use of the drug in reducing irritable bowel...

  • Salix Begins Phase III Studies with Rifaximin. Turner, Tiffany // BioWorld Today;7/2/2008, Vol. 19 Issue 128, p1 

    The article announces that Salix Pharmaceuticals Ltd. has begun initiating enrollment in two Phase III studies for the assessment of the efficacy and safety of rifaximin, in July 2008. Rifaximin is a treatment for nonconstipation irritable bowel syndrome (IBS). Executive director of investor...

  • Salix Pharmaceuticals Outlines Data Presentations at Digestive Disease Week 2011.  // Biomedical Market Newsletter;5/15/2011, p357 

    The article focuses on the Digestive Disease Week® (DDW) 2011 presentations that describe the investigation of various products from Salix Pharmaceuticals Ltd. such as rifaximin and MoviPrep®. It mentions several presentations on rifaximin such as the its effect in cirrhosis and recurrent...

  • Salix Pharmaceuticals Announces Initiation of Target 3: A Phase 3 Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550MG TID in Subjects with Irritable Bowel Syndrome with Diarrhea.  // Biomedical Market Newsletter;2/21/2012, Vol. 21, p1 

    The article informs that Salix Pharmaceuticals has initiated the clinical phase 3 study to determine the efficacy of repeat treatment with rifaximin in patients with Irritable Bowel Syndrome with diarrhea (IBS-D). It further informs that the use of rifaximin has resulted in Clostridium...

  • Salix Anticipates Receipt of FDA Complete Response Letter on XIFAXAN(R) 550 Mg Tablets Supplemental New Drug Application.  // Biomedical Market Newsletter;3/21/2011, p481 

    The article reports on Salix Pharmaceuticals Ltd.'s anticipation of a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for the XIFAXAN(R) (rifaximin) 550 milligrams supplemental New Drug Application (sNDA). It says that Salix expects receiving CRL for the proposed...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics